Biora Therapeutics, Inc.
BIOROTCHealthcare
$0.22
+$0.00(+0.00%)
Market Cap$994994
P/E Ratio—
52W High$0.3802
52W Low$0.15
Biora Therapeutics, Inc. (BIOR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIOR · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2024Report Date: Nov 14, 2024EPS Actual
-$6.08
Est. -$3.85 · -57.9%
Revenue
$0.00B
Est. $0.00B · -86.1%
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Nov 14, 2024
After Market Close
▼ Miss EPS▼ Miss Revenue
BIOR reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2025 | Nov 12, 2025 | — | — | — | — | — | — |
| ◌ Q3 FY2025 | Aug 15, 2025 | — | — | — | — | $0.00B | — |
| ◌ Q2 FY2025 | May 29, 2025 | — | — | — | — | $0.00B | — |
| ◌ Q1 FY2025 | Mar 25, 2025 | -$3.30 | — | — | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$3.85 | -$6.08 | -57.9% | $0.00B | $0.00B | -86.1% |
| ▲ Q3 FY2024 | Aug 12, 2024 | -$4.50 | -$3.50 | +22.2% | $0.00B | — | — |
| ▼ Q2 FY2024 | May 15, 2024 | -$4.50 | -$6.10 | -35.6% | $0.00B | — | — |
| ▼ Q1 FY2024 | Mar 26, 2024 | -$6.00 | -$6.30 | -5.0% | $0.00B | $0.00B | +174300.0% |
Q4 FY2025
Nov 12, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 15, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 29, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 25, 2025
EPS Actual
—
EPS Est.
-$3.30
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$6.08
EPS Est.
-$3.85
EPS Surpr.
-57.9%
Revenue
$0.00B
Q3 FY2024
Aug 12, 2024Beat
EPS Actual
-$3.50
EPS Est.
-$4.50
EPS Surpr.
+22.2%
Revenue
$0.00B
Q2 FY2024
May 15, 2024Miss
EPS Actual
-$6.10
EPS Est.
-$4.50
EPS Surpr.
-35.6%
Revenue
$0.00B
Q1 FY2024
Mar 26, 2024Miss
EPS Actual
-$6.30
EPS Est.
-$6.00
EPS Surpr.
-5.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $-3.71 | $-3.50 | $-3.29 | 1 |
| Q3 FY2024 | $-4.20 | $-3.85 | $-3.50 | 2 |
| Q2 FY2024 | $-4.80 | $-4.50 | $-4.20 | 2 |
| Q4 FY2023 | $-7.46 | $-5.95 | $-4.54 | 2 |
| Q2 FY2023 | $-16.00 | $-16.00 | $-16.00 | 1 |
| Q4 FY2022 | $-13.82 | $-13.82 | $-13.82 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2022 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2024 | Nov 14, 2024 | -57.9% | $2.49 | $2.38 | -4.42% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +22.2% | $5.91 | $5.83 | -1.35% |
| ▼ Q2 FY2024 | May 15, 2024 | -35.6% | $7.38 | $7.15 | -3.12% |
| ▼ Q1 FY2024 | Mar 26, 2024 | -5.0% | $12.20 | $13.30 | +9.02% |
| ▲ Q4 FY2023 | Nov 13, 2023 | +19.4% | $14.20 | $13.70 | -3.52% |
| ▲ Q3 FY2023 | Aug 14, 2023 | +8.1% | $34.60 | $31.70 | -8.38% |
| ▼ Q2 FY2023 | May 15, 2023 | -808.6% | $37.60 | $33.50 | -10.90% |
| ▼ Q1 FY2023 | Mar 30, 2023 | -80.9% | $26.50 | $26.70 | +0.75% |
Q4 FY2024-4.42%
Report Date
Nov 14, 2024
EPS Beat/Miss
-57.9%
Price Before
$2.49
Price After
$2.38
Q3 FY2024-1.35%
Report Date
Aug 12, 2024
EPS Beat/Miss
+22.2%
Price Before
$5.91
Price After
$5.83
Q2 FY2024-3.12%
Report Date
May 15, 2024
EPS Beat/Miss
-35.6%
Price Before
$7.38
Price After
$7.15
Q1 FY2024+9.02%
Report Date
Mar 26, 2024
EPS Beat/Miss
-5.0%
Price Before
$12.20
Price After
$13.30
Q4 FY2023-3.52%
Report Date
Nov 13, 2023
EPS Beat/Miss
+19.4%
Price Before
$14.20
Price After
$13.70
Q3 FY2023-8.38%
Report Date
Aug 14, 2023
EPS Beat/Miss
+8.1%
Price Before
$34.60
Price After
$31.70
Q2 FY2023-10.90%
Report Date
May 15, 2023
EPS Beat/Miss
-808.6%
Price Before
$37.60
Price After
$33.50
Q1 FY2023+0.75%
Report Date
Mar 30, 2023
EPS Beat/Miss
-80.9%
Price Before
$26.50
Price After
$26.70
Avg Beat Reaction-4.42%
Avg Miss Reaction-1.73%
Beat Rate3 / 8 quarters
Largest Move-10.90% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIOR ends December
Biora Therapeutics, Inc. (BIOR) most recently reported earnings on November 14, 2024 for Q4 FY2024, posting EPS of $-6.08 — missing the analyst consensus of $-3.85 by -57.9%. The next BIOR earnings date is expected around September 1, 2026.
Each quarter, investors track BIOR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIOR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIOR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIOR earnings · 5 questionsBiora Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. BIOR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIOR historically reports after market close (AMC).
BIOR earnings datewhen is BIOR earningsBIOR next earnings datewhen does BIOR report earningsBIOR earnings calendar
▸ Source: FMP · Biora Therapeutics, Inc. SEC filings · US GAAP · Biora Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026